Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: TLR3 agonists conjugates - TOLLYS SAS

Next Previous
Drug Profile

Research programme: TLR3 agonists conjugates - TOLLYS SAS

Alternative Names: Antibody-drug-conjugates

Latest Information Update: 30 Jun 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TOLLYS SAS
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; RNA
  • Mechanism of Action Toll-like receptor 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 31 Jan 2022 Preclinical development for Cancer in France (Parenteral)
  • 31 Jul 2018 TOLLYS SAS has patents pending for TLR3 agonists in USA, Australia, Brazil, Canada, China, Japan, Russia, South Korea and European Union (TOLLYS SAS website, June 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top